You have not yet added any article to your bookmarks!
Join 10k+ people to get notified about new posts, news and tips.
Do not worry we don't spam!
Post by : Anis Farhan
The clock is ticking for investors eyeing the Modern Diagnostic & Research Centre Ltd. IPO, as the issue enters its final day of subscription today. Over the past few sessions, the IPO has emerged as a major talking point in the SME segment, driven by heavy demand from retail investors, solid participation from non-institutional bidders, and encouraging signals from the grey market.
In a market environment where investors are increasingly selective, especially in the SME space, the response to the Modern Diagnostic IPO reflects growing confidence in healthcare-linked businesses. Diagnostics, once seen as a niche segment, has now become a structural growth story, supported by rising health awareness, expanding insurance coverage, and increasing reliance on preventive healthcare.
As the bidding window shuts today, investors are weighing whether the strong subscription numbers and grey market cues justify last-minute participation, or whether caution is still warranted.
The Modern Diagnostic IPO is a pure fresh issue, with no offer-for-sale component involved. This means that all proceeds raised from the IPO will directly flow into the company, strengthening its balance sheet and supporting future expansion plans.
The company aims to raise approximately ₹36.89 crore through the issuance of 4.0992 million equity shares. For investors, a fresh issue structure is often viewed positively, as it signals that funds are intended for business growth rather than providing an exit to existing shareholders.
The IPO has been priced in the range of ₹85 to ₹90 per share. Retail investors are required to apply for a minimum lot size of 1,600 shares, translating into a minimum investment of ₹1.44 lakh at the lower end and ₹1.44 lakh to ₹1.44 lakh-plus at the upper band, depending on the final bid price.
While the ticket size is relatively higher compared to some other SME offerings, investor response suggests that the market is willing to commit capital where growth prospects appear convincing.
The IPO opened for subscription on 31 December 2025 and concludes today, 2 January 2026. Post-closure, the basis of allotment is expected to be finalised shortly, followed by refunds and share credits. The company is slated to list on the BSE SME platform, a space that has seen rising investor interest over the past year.
As of the latest available data before the close of bidding, the Modern Diagnostic IPO has witnessed robust oversubscription across investor categories. Retail investors, in particular, have shown overwhelming interest, with subscription figures running far ahead of shares on offer.
Non-institutional investors have also participated actively, signalling confidence beyond just retail enthusiasm. Qualified institutional buyers, though more measured in SME issues, have shown meaningful participation, adding credibility to the overall demand profile.
Heavy oversubscription generally reflects strong market appetite, but it also means tougher odds of allotment, especially for retail investors. In such scenarios, many applicants may not receive shares, which often adds to listing-day anticipation.
However, high subscription alone should not be the sole basis for investment decisions. Investors must consider business fundamentals, sector prospects, and valuation comfort before drawing conclusions.
The grey market premium, an unofficial indicator watched closely by short-term investors, has remained positive for the Modern Diagnostic IPO. Recent trends suggest a premium of around ₹13 to ₹14 per share over the upper end of the price band.
Based on these indications, the stock is expected to list at a price comfortably above its issue price, assuming broader market conditions remain supportive. While GMP is not a guaranteed predictor of listing performance, it often reflects prevailing sentiment and demand-supply dynamics ahead of listing.
In SME offerings, GMP tends to play a more pronounced role due to limited liquidity and smaller issue sizes. A sustained positive premium usually indicates confidence among traders and investors looking for listing gains, though volatility can be higher post-listing.
Modern Diagnostic operates in the healthcare diagnostics sector, offering a range of pathology and radiology services. The company caters to both individual patients and institutional clients, positioning itself as a comprehensive diagnostic service provider.
Diagnostics has emerged as one of the fastest-growing segments within healthcare, driven by increased awareness of early disease detection, lifestyle-related health issues, and preventive testing.
Unlike hospital-based care, diagnostics benefits from repeat usage, relatively asset-light expansion models, and rising test volumes. The shift toward preventive healthcare has further boosted demand for regular diagnostic services, making the sector attractive from a long-term growth perspective.
A significant portion of the IPO proceeds is earmarked for acquiring advanced diagnostic equipment and expanding existing facilities. This is crucial in a sector where accuracy, turnaround time, and technology play a decisive role in customer trust.
Funds will also be utilised to meet working capital needs and reduce outstanding borrowings. A stronger balance sheet can provide operational flexibility and support faster expansion without excessive reliance on debt.
The remaining funds are expected to support general corporate requirements, including operational efficiency, brand building, and administrative needs.
Healthcare stocks often attract investors during uncertain market phases due to their defensive nature. Diagnostics, however, sits at the intersection of defensiveness and growth, offering relatively stable demand with long-term expansion potential.
The SME IPO space has witnessed renewed interest, with several issues delivering strong listing performances. This has encouraged retail participation, especially in companies linked to consumption and healthcare themes.
SME stocks can be more volatile and less liquid compared to mainboard listings. Price swings post-listing can be sharp, both on the upside and downside.
While the diagnostics sector offers growth, competition is intense, with regional and national players constantly expanding. The company’s ability to scale operations while maintaining quality will be critical.
At higher subscription levels and positive GMPs, expectations tend to rise. Any disappointment in post-listing performance or future earnings could lead to corrections.
Once subscriptions close today, the allotment process will begin. Investors who do not receive shares can expect refunds shortly thereafter, while successful applicants will see shares credited to their demat accounts.
The stock is expected to debut on the BSE SME platform in the coming days. Given the strong subscription and positive grey market cues, the listing will be closely tracked by both investors and market analysts.
Short-term investors focusing on listing gains are likely encouraged by the strong GMP and subscription figures. However, they should remain mindful of broader market sentiment on listing day.
Those looking beyond listing gains should evaluate the company’s fundamentals, growth strategy, and financial performance. Healthcare diagnostics can be a long-term story, but execution remains key.
Today marks the final opportunity to subscribe to the Modern Diagnostic IPO, which has generated significant buzz across market circles. Strong subscription numbers, a positive grey market premium, and the appeal of the healthcare diagnostics sector have all contributed to heightened interest.
As the issue closes, investors must balance optimism with caution, keeping in mind both the opportunities and risks associated with SME IPOs. Whether the enthusiasm translates into sustained post-listing performance will become clearer in the days ahead, but for now, Modern Diagnostic stands out as one of the most closely watched IPOs of the moment.
This article is for informational purposes only and does not constitute investment advice. IPO investments are subject to market risks, including volatility and liquidity constraints, particularly in the SME segment. Readers are advised to conduct their own research or consult a qualified financial advisor before making any investment decisions.
Ashes Failure Puts Brendon McCullum Under Growing England Pressure
England’s Ashes loss has sparked questions over Bazball, as ECB officials review Test failures and B
Kim Jong Un Celebrates New Year in Pyongyang with Daughter Ju Ae
Kim Jong Un celebrates New Year in Pyongyang with fireworks, patriotic shows, and his daughter Ju Ae
Dhurandhar Day 27 Box Office: Ranveer Singh’s Spy Thriller Soars Big
Dhurandhar earns ₹1117 crore worldwide by day 27, becoming one of 2026’s biggest hits. Ranveer Singh
Hong Kong Welcomes 2026 Without Fireworks After Deadly Fire
Hong Kong rang in 2026 without fireworks for the first time in years, choosing light shows and music
Ranveer Singh’s Dhurandhar Hits ₹1000 Cr Despite Gulf Ban Loss
Dhurandhar crosses ₹1000 crore globally but loses $10M as Gulf nations ban the film. Fans in holiday
China Claims India-Pakistan Peace Role Amid India’s Firm Denial
China claims to have mediated peace between India and Pakistan, but India rejects third-party involv
